Apply to join the ENABLE-2 consortium
Open Call for new antibiotic programmes
ENABLE-2 is accepting Expressions of Interest (EOIs) from researchers at publicly-funded universities and research institutes throughout Europe.
![Apply to join ENABLE-2](/images/200.58b4b52318eeff6cc4cf1f3/1713433502367/Apply%20to%20ENABLE2%20stor%20bild.jpg)
There are two entry levels:
ENABLE-2 Hit to Lead programme
- Novel Hit compounds with wild-type whole cell antibacterial activity and the potential for development as direct-acting antibiotics for systemic use.
ENABLE-2 Incubator – Hit identification and validation
- Novel compounds with some documented whole cell antibacterial activity against any species or strain (including efflux-deficient or hyperpermeable strains), with a MIC of at least 32 µg/mL, or
- Novel compounds with only documented bacterial target activity.
- Potential for development as direct-acting antibiotics for systemic use.
- Not previously reported to have antibacterial activity.
- Antimicrobial peptides with only membrane perturbation activity are not eligible.
- Novel natural products are eligible.
EOI templates
Contact ENABLE-2
Anders Karlén, Coordinator, Professor
Uppsala University (SE)
anders.karlen@ilk.uu.se, +46 (0)70-167 9177
ENABLE-2 funders
ENABLE-2 is supported by the Swedish Research Council, the National Research Programme on Antibiotic Resistance and Sweden's innovation agency Vinnova.
![ENABLE-2 logotyp](/images/200.58b4b52318eeff6cc4cf49e/1713434482001/enable2%20Logotyp.jpg)